MedTrace Logo

Myeloid Mutations Register in R/R CML

NCT05080829 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2021-10-18

No results posted yet for this study

Summary

The aim of the study is to know the percentage of ABL mutations in patients with chronic myeloid leukemia that relapsed or are refractory to tyrosine-kinase inhibitors measured with a myeloid mutations panel by NGS.

Conditions

  • Chronic Myeloid Leukaemia Recurrent
  • Chronic Myeloid Leukemia, in Relapse

Interventions

DIAGNOSTIC_TEST

Myeloid mutations measurement

Measure of myeloid mutations by NGS when detection of refractory or relapsed CML is done

Sponsors & Collaborators

  • Grupo Cooperativo de Hemopatías Malignas

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-02-28
Completion
2022-03-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05080829 on ClinicalTrials.gov